Qiagen, a medical diagnostics company, is planning to launch a portable coronavirus test that can process up to 30 patient samples per hour and deliver results within 15 minutes. The new test would ...
/PRNewswire-FirstCall/ - QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health ...
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...
QIAGEN N.V. QGEN, together with Myriad Genetics MYGN, will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The endeavor expands upon the ...
QIAGEN N.V. today announced the commercial launch in India of its careHPV ™ Test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with ...
(Reuters) - German diagnostic test maker Qiagen on Tuesday said it planned to launch a COVID-19 antigen test that can provide results in 15 minutes and test about 30 samples in an hour. The company ...
Qiagen's careHPV for use in areas with limited healthcare infrastructure--Courtesy of PATH Dutch molecular diagnostics conglomerate Qiagen ($QGEN) launched its new ...
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results